Literature DB >> 8485025

The effect of tocainide on theophylline metabolism.

C M Loi1, X Wei, B M Parker, M R Korrapati, R E Vestal.   

Abstract

The effect of 5 days of oral tocainide (400 mg every 8 h) on the kinetics of theophylline given as a single 5 mg kg-1 i.v. infusion over 30 min was investigated in eight healthy male nonsmokers. Treatment with tocainide decreased the plasma clearance of theophylline from 37.5 +/- 6.9 (mean +/- s.d.) to 33.7 +/- 5.0 ml kg-1 h-1 (difference -3.8, 95% CI, -1.7 to -5.9; P = 0.004) and increased its terminal elimination half-life from 9.7 +/- 2.5 to 10.4 +/- 2.1 h (difference 0.7, 95% CI, 0.2 to 1.2; P = 0.011). Tocainide decreased the formation clearances of 3-methylxanthine and 1-methyluric acid, but the formation clearance of 1,3-dimethyluric acid was unaltered. These data indicate that tocainide exerts a modest inhibitory effect on theophylline metabolism. The magnitude of this change is substantially smaller than that reported to be produced by mexiletine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485025      PMCID: PMC1381557          DOI: 10.1111/j.1365-2125.1993.tb04163.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Theophylline metabolism by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450.

Authors:  M E McManus; J O Miners; D Gregor; I Stupans; D J Birkett
Journal:  J Pharm Pharmacol       Date:  1988-06       Impact factor: 3.765

3.  Simultaneous determinations by theophylline and its major metabolites in urine by reversed-phase ion-pair high-performance liquid chromatography.

Authors:  K T Muir; J H Jonkman; D S Tang; M Kunitani; S Riegelman
Journal:  J Chromatogr       Date:  1980-11-14

4.  Inhibition of theophylline metabolism by mexiletine in young male and female nonsmokers.

Authors:  C M Loi; X X Wei; R E Vestal
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

5.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

6.  Cigarette smoking and theophylline metabolism: effects of cimetidine.

Authors:  B J Cusack; G W Dawson; G D Mercer; R E Vestal
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

7.  Effect of cigarette smoking on mexiletine kinetics.

Authors:  O Grech-Bélanger; M Gilbert; J Turgeon; P P LeBlanc
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

8.  Characterization of human liver cytochromes P-450 involved in theophylline metabolism.

Authors:  M A Sarkar; C Hunt; P S Guzelian; H T Karnes
Journal:  Drug Metab Dispos       Date:  1992 Jan-Feb       Impact factor: 3.922

9.  Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man.

Authors:  R E Vestal; C E Eiriksson; B Musser; L K Ozaki; J B Halter
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

10.  Tocainide kinetics and metabolism: effects of phenobarbital and substrates of glucuronyl transferase.

Authors:  A T Elvin; D Lalka; K Stoeckel; P du Souich; J E Axelson; L H Golden; A J McLean
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

View more
  1 in total

Review 1.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.